Because every major market keeps its own list of banned and restricted ingredients, its own SPF ceiling, and its own pre-market filing rules, the same skincare product usually cannot carry one identical formula everywhere. A version sold in the European Union, a version sold in China, and a version sold in the United States are often three different formulas built from the same product idea. This is not a quality gap — it is the normal result of regulatory design, and it is something a contract manufacturer plans for from the first sample.
What Actually Changes Between Markets?
Three things drive most of the differences you will see between regional versions of one product.
- Banned and restricted ingredient lists. The EU Cosmetic Products Regulation, China's CSAR framework under the National Medical Products Administration (NMPA), and the US FDA each maintain separate negative lists. A preservative permitted in one region can be banned or capped in another.
- Approved sunscreen filters and SPF ceilings. Sun care is where formulas diverge the most. The set of approved UV filters is not the same across regions, and the maximum labelled SPF differs, so a sunscreen that is legal in one market may need a rebuilt filter system in another.
- Animal testing and pre-market filing. China historically required animal testing for imported cosmetics, with narrowing exceptions; the EU bans cosmetic animal testing outright. Filing models also differ — China runs a filing or registration system through NMPA, the EU uses CPNP notification with a Responsible Person, and the US uses facility registration and product listing under MoCRA.
Why "One Formula for Every Market" Usually Fails
The appeal of a single global formula is real: one dossier, one batch record, lower cost. The problem is that regional negative lists are not aligned. A preservative that is standard in the US may be restricted in the EU. A UV filter widely used in Asia may not be accepted by the US FDA. When a brand tries to push one formula through every gateway, it tends to hit a wall in the strictest market and then has to reformulate anyway — usually under time pressure, after tooling and packaging are already locked.
A more workable approach is to design for the strictest relevant market first, then trim for the others. If a formula clears the EU's negative list and SPF rules, it is usually easier to adapt for the US and China than the reverse. That sequencing is a formulation decision, not a marketing one. Brands that skip it usually pay twice — once in reformulation cost, and again in launch delays that miss the seasonal window they planned around. Building the market list into the brief on day one is far cheaper than discovering a blocked ingredient after tooling is locked.
How a Manufacturer Localizes a Formula for You
From the production side, multi-market localization is a structured process rather than a rewrite each time. At CHONGSHENG FUTURE (重生未来), the typical path looks like this:
- Map the target markets. We confirm which regions the brand will sell in, because that decides which negative lists and filing routes apply.
- Screen the base formula. Every active, preservative, UV filter and colorant is checked against each market's permitted list before any batch is made.
- Swap at the component level. Where an ingredient is blocked in one market, we propose a functionally similar alternative that keeps the product concept intact — same texture goal, same claim level, different component.
- Re-run stability and challenge testing. Any changed component can shift emulsion behaviour, so the adjusted formula goes back through stability and preservative efficacy testing before release.
This is why working with an OEM/ODM partner that already holds the market knowledge shortens the loop: the substitutions are planned, not discovered at customs.
How Early Should You Plan for a Multi-Market Launch?
Filing lead time is the part brands underestimate. A China filing for a regular (non-special) cosmetic can be relatively quick, but special categories such as sunscreen require registration that can run much longer. The EU CPNP notification is faster, yet the safety assessment behind it still takes weeks. A simple planning horizon:
| Market | Core step | Typical lead time to plan for |
|---|---|---|
| European Union | CPNP notification + Responsible Person + safety assessment (CPSR) | Several weeks for the dossier |
| China (regular cosmetic) | NMPA filing through a China-based Responsible Person | Weeks, plus testing where required |
| China (special cosmetic, e.g. sunscreen) | NMPA registration | Materially longer; plan months ahead |
| United States | Facility registration + product listing under MoCRA | Weeks, after safety substantiation is ready |
These are planning ranges, not guarantees — actual timing depends on product category, test scope and how complete the dossier is on day one.
What to Prepare Before Talking to a Manufacturer
If you are scoping a multi-market line, bring these to the first technical call so the formula is built right the first time:
- The exact list of target markets, in priority order.
- Your intended claims per market, so the formula and evidence match the local rules.
- Any "clean" or "free-from" lists your brand commits to, since they constrain preservative choice.
- Packaging and launch date, because filing and testing windows must fit the schedule.
CHONGSHENG FUTURE (重生未来) runs OEM and ODM skincare programs across the EU, China and US frameworks, and helps brands turn one product idea into market-ready formulas instead of last-minute rewrites. If you are planning a multi-region launch, the cheapest time to localize the formula is before the first batch, not after a market rejects it.